


## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

# Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	, ,
Company	<u>General</u>
GlaxoSmithKline (depemokimab)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Allergy UK	Board of Community Health Councils in
Asthma + Lung UK	Wales
Asthma Relief Charity	British National Formulary
Asthma Trust for Asthmatic Children	Care Quality Commission
European Federation of Allergy &	Department of Health - Northern Ireland
Airways Diseases Patient Association	Healthcare Improvement Scotland
• Fifth Sense	Medicines and Healthcare products
NARA - The Breathing Charity	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
The Samter's Society	NHS Confederation
Live Miles and the Constitution of the Constit	Scottish Medicines Consortium
Healthcare professional groups	Welsh Government
Association for Respiratory  Tack and Physicals are	Welsh Health Specialised Services
Technology and Physiology	Committee
Association of Respiratory Nurse     Specialists	Donaible commenter commenter
Specialists	Possible comparator companies
British Geriatrics Society     British Bandintria Bandintria Society	AstraZeneca, (benralizumab,     tazanalumab)
British Paediatric Respiratory Society     British Phinalogical Society	tezepelumab)
British Rhinological Society     British Thoronic Society	Novartis (omalizumab)     Sanafi (dupilumab)
British Thoracic Society      If D. IN: Interestition I upg Diseases.	Sanofi (dupilumab)     TEVALUK (reglizumab)
ILD-IN: Interstitial Lung Diseases     Interdisciplinary Network	TEVA UK (reslizumab)
National Heart and Lung Institute	Relevant research groups
Neonatal and Paediatric Pharmacists	Asthma, Allergy and Inflammation
Group	Research Charity
<ul> <li>Primary Care Respiratory Society UK</li> </ul>	British Association for Lung Research
<ul> <li>Royal College of General Practitioners</li> </ul>	Cochrane Airways Group
Royal College of Nursing	Genomics England
Royal College of Paediatrics & Child	MRC Clinical Trials Unit
Health	National Institute for Health Research



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> </ul>	Associated Public Health groups  • Public Health Wales  • UK Health Security Agency
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare

Provisional stakeholder list for the evaluation of depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447





Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.